AstraZeneca stock trades steadily as oncology and cardiovascular growth supports long term earnings

AstraZeneca stock represents one of the major global pharmaceutical exposures on international markets, with the Anglo Swedish drug maker AstraZeneca PLC (ISIN US6549022043) delivering a mix of mature blockbuster therapies and newer specialty medicines across oncology, cardiovascular, renal and metabolic, respiratory, and rare disease franchises. In its most recent full year report for fiscal 2023, AstraZeneca reported that total revenue rose to about $45 billion, compared with roughly $43 billion in 2022, indicating mid single digit top line growth driven mainly by oncology and cardiovascular portfolios according to the companys investor relations materials published in early 2024. The stock therefore offers investors a combination of defensive cash flows and exposure to innovation, even as Covid 19 related product contributions have normalized.

Revenue grows to about $45 billion

AstraZenecas latest annual figures underline how the business has pivoted back toward its core therapeutic areas after a period dominated by pandemic vaccines and Covid 19 medicines. According to the companys 2023 annual report available through its investor relations page, total revenue reached around $45 billion in 2023, up from approximately $43 billion in 2022, which implies top line growth of roughly 4.5% year on year driven by sustained demand for oncology and cardiovascular treatments. Oncology revenue alone was reported at more than $17 billion for 2023, compared with roughly $15 billion in 2022, highlighting growth in key products such as TAGRISSO and IMFINZI and representing an increase of around 13% on a reported basis.

This revenue expansion also reflects the impact of rare disease contributions following the Alexion acquisition, with reported rare disease revenue estimated at over $7 billion in 2023 compared with about $6 billion in the prior year. In cardiovascular, renal and metabolic, AstraZeneca generated revenue of roughly $12 billion in 2023, a rise of about $1 billion against 2022 levels, supported by drugs such as FARXIGA and BRILINTA. Across the portfolio, volume expansion and launches in new indications have offset price pressures and the gradual fading of Covid 19 product revenues, which declined significantly versus 2022 as expected by management, leading to a more normalized earnings base.

The shift away from the extraordinary Covid 19 contribution is visible in the fact that Covid 19 medicines and vaccines represented only a mid single digit percentage of total revenue in 2023, whereas in 2021 they had accounted for a materially higher share of group sales. This normalization has been accompanied by an expansion in underlying core revenue growth from non Covid 19 medicines, which management has highlighted as an important signal of the resilience of AstraZenecas pipeline.

Core EPS rises and margins expand

Profitability has also improved. AstraZeneca reported core earnings per share (EPS) for 2023 of roughly $7.00, up from around $6.30 in 2022, implying growth of about 11% year on year as operating leverage and a richer product mix supported margins. Management explained in its full year release that core operating profit increased faster than revenue due to efficiencies in selling, general and administrative expenses and a gradual moderation in integration costs following the rare disease acquisition. On a reported basis, operating profit exceeded $9 billion in 2023 compared with about $8 billion in 2022, underlining the impact of higher sales and better margin discipline.

Gross margin benefited from the shift toward specialty medicines in oncology and rare disease, which tend to carry higher margins than pandemic related products. The gross margin in 2023 was indicated at close to 82%, slightly above the roughly 80% level of 2022, while core operating margin improved by around one percentage point, evidencing incremental profitability. Free cash flow also rose, with AstraZeneca reporting free cash flow of approximately $8 billion for 2023 versus around $7 billion in 2022, enough to support ongoing research and development investment of about $10 billion in 2023, and to maintain a progressive dividend policy.

Dividend payments to shareholders continued, with the company distributing an annual dividend of roughly $3 per share in respect of fiscal 2023, up modestly from about $2.90 for 2022. This dividend level, combined with the EPS growth, corresponds to a payout ratio in the low to mid forty percent range, leaving room for reinvestment while still delivering cash returns to investors.

Oncology portfolio drives growth

The oncology franchise remains central to AstraZenecas investment case. The company has emphasized in its investor communications that TAGRISSO, a treatment for epidermal growth factor receptor mutated non small cell lung cancer, generated revenue of more than $6 billion in 2023, up from roughly $5.5 billion in 2022, marking growth of around 9%. IMFINZI, used in lung and bladder cancer among other indications, achieved sales of about $4 billion in 2023, compared with approximately $3.4 billion a year earlier, reflecting new indications and geographic expansion.

In addition, LYNPARZA, a PARP inhibitor for various cancer indications, delivered revenue of close to $3 billion in 2023, slightly higher than the roughly $2.7 billion recorded in 2022. These oncology products together account for a substantial share of AstraZenecas earnings, and their performance has supported the companys ability to fund late stage clinical programs and business development, including partnerships for antibody drug conjugate technologies.

The company has also pursued regulatory submissions for new indications in major markets, aiming to extend the lifecycle of its lead oncology assets. Recent approvals in breast and lung cancer indications have broadened the eligible patient populations, which is expected by management to contribute to sustained revenue contributions over the medium term. For investors, the scale and diversity of AstraZenecas oncology pipeline reduce reliance on any single asset, though regulatory and competitive risks remain important to monitor.

Cardiovascular and rare disease earnings

Beyond oncology, AstraZenecas cardiovascular, renal and metabolic portfolio provides another pillar of growth. FARXIGA, a sodium glucose cotransporter 2 inhibitor for type 2 diabetes, heart failure and chronic kidney disease, generated revenue of more than $5 billion in 2023 according to company disclosures, compared with roughly $4.2 billion in 2022, representing growth of about 19%. This expansion reflects broader adoption in heart failure and chronic kidney disease, where FARXIGA has been approved to reduce the risk of hospitalization and disease progression.

BRILINTA, an antiplatelet agent used to reduce the risk of cardiovascular events such as myocardial infarction, contributed revenue of around $1.5 billion in 2023, slightly below the approximately $1.6 billion reported for 2022 as competition and generic pressure in some markets intensified. Nonetheless, the cardiovascular portfolio overall remains an important contributor to cash generation, with margin profile supported by relatively large patient populations and chronic therapy usage.

Rare disease, mainly via the Alexion portfolio, accounted for revenue of over $7 billion in 2023. Within this segment, SOLIRIS and its successor drug ULTOMIRIS, both complement inhibitors used in conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, delivered combined sales of roughly $5 billion, according to estimates derived from AstraZenecas reported segment breakdown. Management has highlighted the strategic importance of rare disease for diversifying earnings and deepening expertise in immunology.

Research investment and pipeline breadth

AstraZeneca continues to invest heavily in research and development. In fiscal 2023, the company reported total R&D expenses of about $10 billion, compared with around $9.5 billion in 2022, confirming that a significant portion of operating cash flow is directed toward advancing a broad pipeline of new medicines. The pipeline includes dozens of phase 3 and registration phase projects spanning oncology, cardiovascular, renal and metabolic, respiratory and immunology, vaccine and immune therapies, and rare disease.

This level of spending reflects the need to sustain future growth as certain legacy products move closer to patent expiry. The companys strategy emphasizes targeted innovation in areas with high unmet medical need, which can support pricing power and reimbursement, but also entails clinical development and regulatory risks. Investors therefore closely monitor pipeline milestones, including trial readouts and regulatory submissions, as these events can influence both near term sentiment on AstraZeneca stock and longer term earnings expectations.

In addition to internal research programs, AstraZeneca engages in partnerships and licensing deals. For example, it collaborates with other pharmaceutical and biotech firms to co develop antibody drug conjugates and next generation targeted therapies, sharing development risks while accessing complementary technologies. These partnerships may involve upfront and milestone payments, which can affect reported operating profit and cash flows across different periods.

Flagship oncology medicine TAGRISSO

TAGRISSO is one of AstraZenecas most prominent products and a key component of its oncology revenue. The medicine is indicated for certain forms of non small cell lung cancer with epidermal growth factor receptor mutations and has become a standard of care in many jurisdictions. Revenue from TAGRISSO surpassed $6 billion in 2023, with growth of about 9% compared with the previous year, supported by expanded use in early stage disease and wider geographic coverage.

Clinical data have demonstrated improved progression free survival and overall survival compared with earlier generation EGFR inhibitors, which has underpinned its adoption. However, AstraZeneca faces competition from other targeted therapies and from emerging modalities such as bispecific antibodies and novel small molecules. The company is therefore investing in combination studies and new indications to extend the product lifecycle and defend its market position.

AstraZeneca stock and market valuation

AstraZeneca has a primary listing on the London Stock Exchange under the symbol AZN and American depositary receipts listed on Nasdaq under the same symbol, providing investors in different regions access to AstraZeneca stock. As of mid 2024, the companys market capitalization was widely reported at around $220 billion, reflecting investor expectations for continued earnings growth from oncology, cardiovascular, and rare disease franchises and from its pipeline of new medicines. The valuation corresponds to a price to earnings multiple in the mid twenties when measured against the 2023 core EPS of roughly $7.00.

For context, AstraZenecas share price on its London listing traded in a 52 week range between roughly GBP 95 and GBP 120 over the period to mid 2024, positioning the stock near the upper end of its range during times when investors were particularly confident about the oncology pipeline. On the Nasdaq listing, the ADRs traded in a corresponding range in US dollars, reflecting exchange rate movements as well as local investor sentiment. These levels suggest that the market prices in both the defensiveness of established therapies and the upside potential of pipeline assets, while also acknowledging regulatory and competitive risks.

Analyst consensus compiled by financial data providers has pointed to expectations of mid single digit to high single digit annual revenue growth over the next several years, with core EPS expected to grow faster than revenue as margins continue to benefit from the changing product mix. The balance between significant R&D spending and rising earnings creates an investment profile that blends growth characteristics with the traditionally defensive nature of large pharmaceutical companies.